Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus
Chinese SLE Treatment and Research group (CSTAR) registry: I. Major clinical characteristics of Chinese patients with systemic lupus erythematosus
复制标题
DOI：
10.1177/0961203313499086
复制
发表时间：
2013-10-01
期刊：
影响因子：
2.6
通讯作者：
Zeng, X.
中科院分区：
文献类型：
--
作者：
Li, M.;Zhang, W.;Zeng, X.
中国系统性红斑狼疮（SLE）治疗研究组（CSTAR）提供中国SLE的主要临床特征，并建立平台，为未来的基础和临床研究提供资源。CSTAR最初是一种多中心、连续和前瞻性设计。这些数据来自中国30个省的104个风湿病中心。登记的患者需要满足四个或四个以上的美国风湿病学会（ACR）SLE分类标准。所有CSTAR中心均使用相同的方案指导方法提供统一的评价，包括人口统计学数据、临床特征、实验室检查和疾病活动性评价。还收集了患者样本，包括DNA样本和血清，用于进一步的质量控制和其他研究。对2104项基线评价的初步分析可用于本分析。在1914名女性和190名男性患者中（F：M=10.1），平均发病年龄为29.2岁，1年后确诊为30.3岁。2002例患者中有风湿性疾病家族史者84例（4.2%），其中SLE患者34例（1.7%）。此外，在2026例经验中记录了107例（5.2%）异常妊娠。将CSTAR队列的特征与来自其他研究的类似规模队列进行比较。我们发现，56.1%的患者并发血液系统疾病，而欧洲患者仅为18.2%。此外，47.4%的患者出现肾病，而欧洲患者为27.9%。相反，神经系统表现仅见于4.8%的中国SLE患者，而欧洲患者为19.4%，美国患者为12.1%，马来西亚患者为22.8%，拉丁美洲患者为26.4%。肺动脉高压和间质性肺疾病分别为3.8%和4.2%的中国狼疮患者的并发症。CSTAR登记研究提供了中国SLE患者的流行病学数据和表型，并证明了种族间的一些差异。临床数据和生物样本将是未来国家和国际合作转化研究的宝贵资源。
The Chinese systemic lupus erythematosus (SLE) treatment and research group (CSTAR) provides major clinical characteristics of SLE in China and establishes a platform to provide resources for future basic and clinical studies. CSTAR originated as a multicentre, consecutive, and prospective design. The data were collected online from 104 rheumatology centers, which covered 30 provinces in China. The registered patients were required to meet four or more of the American College of Rheumatology (ACR) criteria for the classification of SLE. All CSTAR centers use the same protocol-directed methods to provide uniform evaluations, which included demographic data, clinical features, laboratory examinations, and disease activity evaluations. The patient samples, including DNA samples and sera, were also collected for further quality controls and additional studies. Preliminary analysis from 2104 baseline evaluations was available for this analysis. Of 1914 female and 190 male patients (F:M=10.1), the mean age at onset was 29.2 y with confirmed diagnosis one year later at the age of 30.3 y. Eighty four (4.2%) of 2002 patients had a family history of rheumatic diseases, including 34 (1.7%) cases with SLE. In addition, one hundred and seven (5.2%) abnormal pregnancies were recorded among 2026 experiences. The characteristics of the CSTAR cohort were compared to similarly sized cohorts from other studies. We found that 56.1% of patients presented with concurrent hematological disorders compared to only 18.2% of European patients. Moreover, 47.4% of patients presented with nephropathy compared to 27.9% of European patients. Conversely, neurological manifestations were only seen in 4.8% of Chinese SLE patients compared to 19.4% of European patients, 12.1% of U.S. patients, 22.8% of Malaysian patients and 26.4% of Latin Americans. Pulmonary arterial hypertension and interstitial lung diseases were complications identified in 3.8% and 4.2% of Chinese lupus patients, respectively. The CSTAR registry has provided epidemiological data and phenotypes of Chinese patients with SLE, and has demonstrated several differences between ethnicities. Clinical data and biologic samples would be valuable resources for future translational studies with national and international collaboration.